Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEN1112
- Development stage
- Preclinical
- Lead developer
- Menarini
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MEN1112 is a humanized, Fc-engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody that targets the bone marrow stromal cell antigen 1 (BST1/CD157). It was developed as an antineoplastic agent with the primary mechanism of action being antibody-dependent cellular cytotoxicity (ADCC), particularly through natural killer (NK) cell-mediated cytotoxicity. The drug was designed to enhance immune-mediated killing of CD157-expressing cells and has shown potent in vitro and ex vivo activity against acute myeloid leukemia (AML) cells. Developed by Menarini and Oxford BioTherapeutics, it reached phase I clinical trials for relapsed or refractory AML but development for this indication has been discontinued[1][3][5][6][8].
- Other names
- anti-CD157 monoclonal antibody MEN1112anti-CD-157 monoclonal antibody MEN1112anti-CD 157 monoclonal antibody MEN1112
02
Targets
BST1 (CD157)
Beyond the preview
Go deeper on MEN1112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEN1112.